Mitochondrial research

BPC-157 reconstitution protocol, Canadian researcher's quick reference

Published 2026-07-28 · Pure North Peptides Editorial · Canada

Published JUL 28, 2026·5 min read·Pure North Editorial

Elamipretide concentrates in the inner mitochondrial membrane by binding cardiolipin, not by receptor engagement. What that means for bioenergetics assays.

Most peptides reach their target by binding a receptor. SS-31 does not, and that is precisely why it is useful as a tool compound.

The targeting mechanism is physical chemistry

SS-31 (elamipretide) is a tetrapeptide with an alternating aromatic-cationic motif: D-Arg-Dmt-Lys-Phe-NH2. That alternating charge pattern drives selective accumulation in the inner mitochondrial membrane, where it associates with cardiolipin — a phospholipid found almost exclusively there. No transporter, no receptor, no active uptake step.

What cardiolipin binding does

Cardiolipin organises the cristae and holds the electron-transport chain complexes in supercomplex arrangements. When cardiolipin is peroxidised or disordered, those arrangements loosen and electron transfer becomes leakier. Published work associates SS-31 binding with stabilised cristae architecture, better-organised supercomplexes, higher ATP output, and reduced escape of reactive oxygen species.

The important nuance for assay design: SS-31 is not a free-radical scavenger. It reduces ROS production by improving the efficiency of the chain, rather than by mopping up radicals after the fact. An antioxidant-capacity assay will therefore under-report it, and comparing it head-to-head against a scavenger like NAC in such an assay produces a misleading result.

Assay implications

  • Use respirometry. Oxygen-consumption-rate profiling (Seahorse or equivalent) reads the mechanism directly; total-antioxidant assays do not.
  • Look at cristae morphology. Electron microscopy or cristae-density quantification captures the structural claim.
  • Blue-native PAGE for supercomplex assembly if the question is chain organisation.
  • Pair with a cardiolipin-deficient control where possible; if the effect survives cardiolipin depletion, something else is happening.

Selected literature

  • Birk AV et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261.
  • Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent. Br J Pharmacol. 2014;171(8):2029-2050.

Stocked in 10 mg and 50 mg research sizes: SS-31 reference standard · background in the peptide library. For laboratory research use only.

Continue reading